Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

another antibiotic. Results showed that Emblaveo had similar cure rates compared with meropenem for treating complicated intra-abdominal infections (76.4% vs 74%). Emblaveo also showed lower ...

and health regulators have called for the development of newer treatments as resistance to older antibiotics grows. Intra-abdominal infections (IAIs) are a group of infections that occur in the ...

Opens in a new tab or window According to the company, the product is the first and only fixed-dose, intravenous, monobactam/beta-lactamase inhibitor combination antibiotic to receive FDA approval.

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options. Emblaveo (aztreonam and avibactam), is the first ...